Advisory Board Members

The Advisory Board of the Scottish Lifesciences Association is Chaired by Duncan Moore.

Duncan Moore

Chairman, Lamellar Biomedical

Duncan Moore is the Chairman of Lamellar Biomedical and an Advisory Board member of the Scottish Lifesciences Association.He is currently a partner at East West Capital.Prior to that he was a managing Director at Morgan Stanley where he was global head of healthcare research.  During this time he led the equity market positioning of a number major healthcare companies including Wellcome PLC, Sulzer Medica, Almirall and Grupo Rovi. 

He trained as a biochemist at the University of Leeds and has a PhD from the University of Cambridge.  Whilst at Cambridge he co-founded a molecular diagnostics company with 2 colleagues.  Following his move to the capital market in 1985 he was involved in setting up the bankInvest BioVenture funds and sat on the board of these funds until they were sold in 2009.

 

Ken Sutherland

President, Canon Medical Research Europe Ltd.

Ken currently holds the position of Company President of Canon Medical Research Europe Ltd in Edinburgh (formerly Toshiba Medical Visualizations Systems Europe) with responsibility for a team of 125 computer scientists, data analysts and clinical experts. This group is responsible for research and development of advanced visualization technology and novel clinical applications for 3D medical imaging as part of Canon Medical Systems Corporation. In this post Ken is part of Canon Medical’s Global R&D leadership and serves as an industry advisory to the Scottish Government on the Life Sciences Industry Leadership Group (LiSAB).

Ken returned to Edinburgh in August 2007 to join Toshiba Medical as R&D General Manager, having previously held the post of Operations Director for a European multinational running its imaging R&D facility in Cambridge, UK. Ken studied Electronics and Computer Science at Edinburgh University and has a PhD in image analysis and four years postdoctoral research experience in medical image analysis.

 

Hugh Griffith

CEO, ALIDA CAPITAL INTERNATIONAL

Hugh has 20 years experience in the biopharmaceutical industry, having held CEO, COO and Executive Director positions.   He is CEO and gatekeeper of Alida Capital International, a specialist biopharmaceutical business angel syndicate, which he formed in 2009. He is actively involved in several emerging biopharmaceutical companies, and is co-founder and CEO of NuCana BioMed, an oncology focused biopharmaceutical company.

As former COO of Bioenvision, Hugh led the company’s operations from start-up to a global, fully integrated, NASDAQ listed biopharmaceutical company.  He was instrumental in increasing Bioenvision’s market capitalization from $22 million to $345 million in 5 years, culminating in the company’s successful acquisition.  Hugh was responsible for the strategic direction and implementation of the company’s core programmes, including fund raising; non-clinical and clinical development; manufacturing; regulatory; medical; PV; commercial build-out and product launches.
Hugh has wide pharmaceutical experience having held numerous positions in Abbott Laboratories and Parke-Davis Warner Lambert. He has an active global network of business angels, researchers, regulators, analysts, and institutional investors. Hugh currently serves on the Angel Leaders Forum; the Saltire Foundation. He chairs the SLA's Finance Special Interest Group.

Related Stories

NuCana BioMed Secures $10.4 Million Series A Financing

NuCana plc Announces Pricing of Initial Public Offering

Jim Reid

Chairman, Sistemic

A “Global Scot” for his work in the international biotechnology and pharmaceutical industries, Jim was the Winner of the Ernst & Young Entrepreneur of the Year for Science and Technology for both Scotland and at the UK National finals in 2005.  Jim developed his early career in blue-chip organisations in many parts of the world including Hoffman la Roche, Chiron and Organon, progressing from the research bench to business management before returning to Scotland in 1999 to join the Board of Axis Shield plc.

Since then he has utilised this experience to contribute widely to the life sciences industry in Scotland. Jim has been instrumental in the formation and development of more than 10 companies in the sector and has successfully exited from 2 of these companies including the highly acclaimed sale of Haptogen to Wyeth, one of the world’s top pharmaceutical companies. He was awarded the Outstanding Contribution to Life Sciences in 2010. Jim is now expanding his work with early stage Life Science companies, picking the “winners” of the future in this key sector of the Scottish economy.  He is a member of the Advisory Board of the Scottish Lifesciences Association, and chairman of its Cell Therapy Special Interest Group.

Related Stories

Sistemic Sales Gain Pace in 2011

Reid plans expansion at Sistemic

Deborah O'Neil

CEO/CSO, Novabiotics Ltd

An immunologist by training with over a decade's experience in the field of natural antimicrobials, Deborah studied at University College London and then worked in laboratories in San Diego and Ghent before moving to Aberdeen. Novabiotics was started in order to fully develop the commercial potential of novel antimicrobial peptide therapies. Deborah is CEO/CSO at Novabiotics Ltd based in Aberdeen.

Andrew Waddell

Managing Director, TMQA

Dr Waddell, one of the leading motivational trainers in the life sciences industry, specialises in development of excellence in staff and systems.  He is a Senior Member of the American Society of Quality and a former Director and Chairman of the Research Quality Association from whom he received the RQA Award for extended, outstanding services.

Dr Waddell initially taught and researched in Pathology at the University of Edinburgh’s Medical School and was the Government’s Professional Adviser in Health Education for Scotland.  He then became Head of Quality and Training at Inveresk Research for nineteen years, when he was responsible for GXP compliance and the award of ISO 9001; he also developed a Regulatory Affairs service and managed of a subsidiary Biotechnology company.  He was an adviser to the OECD during the development of the original OECD Principles of Good Laboratory Practice.  Dr Waddell is now Managing Director of TMQA, which provides customers with training, consultancy and audits to UK and international quality standards.  A lecturer in Europe and the USA, he has wide experience of working with government and industry bodies. He has recently joined the Advisory Board of the Scottish Lifesciences Association, and is the chairman of its Regulatory & Quality Special Interest Group.

Dr Waddell is also an international football referee, until recently a member of FIFA’s World Cup list, and a broadcaster with the BBC.  In 2007 he was appointed to the Council of the Scottish Football Association and is now a member of its Professional Game Board.

Susan McGoldrick

Consultant, The CNS Company

Susan McGoldrick has worked in the pharmaceutical industry for 20 years in senior executive management roles initially with Scotia Pharmaceuticals and then Laxdale Ltd, a small biotech company specializing in CNS drug development. In 2006 Susan founded and ran until its disposal in 2014, a CRO specializing in clinical trials in CNS disorders. Susan has an in-depth knowledge of drug development process particularly the challenges of conducting clinical trials in CNS disorders and contracting and working with CROs. Susan also has a wealth of knowledge in clinical trial financial management, intellectual property management and licensing as well as legal and contractual issues specific to the pharmaceutical and CRO industries.
Susan is a member of the Institute of Chartered Accountants of Scotland and qualified with Ernst & Young. Susan is currently Head of Contracts for The Clinical Trial Company and advises The CNS Company on CNS clinical trials.
 

Ross Nicol

Partner, Dentons

Ross is a Partner in the IP and Technology Team at Dentons, having joined the firm in 2001 when it was MMS. Ross advises clients upon non-contentious intellectual property and information technology matters, with a focus on commercial arrangements relating to technology creation and exploitation. Ross also advises upon intellectual property aspects of corporate transactions, e-commerce, Data Protection/Freedom of Information compliance and franchising.

Ross works with a broad spectrum of clients, from individuals and start up companies through to major UK PLCs, in a variety of sectors, including life sciences, food and drink, financial services and software. He spent time on secondment with an international pharmaceutical company.

Doreen Davidson

Senior Director HR, Charles River Laboratories

Doreen is responsible for the HR and Training functions for the European Preclinical Services (covering Edinburgh, Ireland and Germany) of Charles River Laboratories.  She manages a team of staff responsbile for all HR policies and activities including recruitment & selection, appraisal and training, education / industry links (work placements, school and university liaison, careers events etc) and industrial relations issues.

In addition, Doreen is Secretary to the Trustees of the Inveresk Research Pension & Life Assurance Plan; a members of the Court of the University of Edinburgh, Chair of the Scottish Life Sciences Association HR Special Interest Group and a member of the People Workstream of the Scottish Government's Life Sciences Advisory Board.   She is a member of the Advisory Board of the Scottish Lifesciences Association, and chairs the HR Special Interest Group.

Earlier in Doreen's career, she worked as Group Personnel Officer for Brown Boveri South Africa Pty, where she was responsible for the HR function for the company's 5 locations in the Witwatersrand area of Johannesburg.  She has a BA from University of Edinburgh.

 

Cammy Mitchell

Site Director, Irvin, GSK

Cammy joined GSK as a Mechanical Apprentice in 1987. He has progressed in his career across multiple disciplines including becoming a Lean and Six Sigma Expert and working as a practitioner within the Operational Excellence team as well as Operational Maintenance Manager. He was promoted onto the Irvine Site Leadership Team as Production Manager in 2010. Cammy was appointed Irvine Engineering Director in 2012. A role he held until his most recent appointment to Site Director for the Irvine site in April 2018.

Paul McBarron

Executive VP Finance, Cyclacell Pharmaceuticals Inc

Paul has 25 years of experience in pharmaceuticals and in 2002 joined Cyclacell, a spin out company from the University of Dundee.  The company is developing several oncology therapies, and has a number of programmes in clinical development.  It has raised $250m to date, and is listed on the US NASDAQ stock exchange.

Prior to joining Cyclacell, Paul served as a financial executive with a number of large pharmaceutical companies, and in 1996 moved to Shire Pharmaceuticals where he was Director of Corporate Finance and Group Financial Controller.  He helped guide Shire through 6 corporate acquisitions after which it was valued at $5bn.  Paul is a qualified chartered accountant, a member of the Scottish Government's Life Sciences Advisory Board and sits on the Advisory Board of Scottish Enterprise Tayside.  

 

Michael Dalrymple

Director of Business, MRC Technology

As Director of Business Development, Mike coordinates business development strategy for MRC Technology, a technology transfer company whose largest client is the Medical Research Council (MRC).

After a career in academic research, Mike’s first job in the commercial sector was at Inveresk Research. In 1990, Mike joined PPL Therapeutics where he rose from molecular biology team leader to Head of New Product Discovery. After 8 years at PPL, through a period of rapid company growth, an IPO on the LSE and the creation of several famous sheep, Mike left to become CEO of the MRC Collaborative Centre in Edinburgh, an organisation that was subsumed into MRC Technology in 2000.  

Mike has taken a number of senior roles within MRC Technology: Director of Applied Research, Director of Intellectual Property and, most recently, Director of Business Development. He was directly involved in creating the MRC’s Development Gap Fund (a proof of concept seed fund for MRC Units), the Centre for Therapeutics Discovery (MRC Technology’s early stage drug discovery facility) and leading a number of major licensing deals.  Mike has also been the MRC nominee director on the boards of several companies including Domantis,  Aptuscan, Anacrine and Virogen (the latter as Chairman). On a personal level he is the long suffering supporter of a well known and hugely unsuccessful Scottish football team and has an interest in the history of the Royal Navy in the Firth of Forth. 

Gavin D Clark

Director, Lamellar Biomedical

Gavin's extensive career spanned positions in a number of major companies including Janssen, Bayer and Novartis before he became successively Global Licensing Director at GSK, and VP Business Development for Tibotec NV.  In 2002 he founded Dublin based Procela Partners, with clients in the CNS, Infectious Diseases, Oncology, and Systems Biology fields.
 
In 2009 he established Marlin Bioconsulting in UK of which he is MD.  He cofounded  and was CBO at MGB Biopharma, which licensed infectious diseases technology from University of Strathclyde. He continues  as a Non-Executive Director of Lamellar Biomedical.  Additionally he is both an Enterprise Partner and a member of the Life Sciences Commercial Advisory Panel at the University of Strathclyde.
 

Scott Johnstone

CEO, SLA

Scott has been CEO of the Scottish Lifesciences Association since 2011. He started his career with a large pharmaceutical company where he gained technology transfer and R&D experience with a broad range of companies including Fisons (UK), Kevex based in California and Applied Research Laboratories based in Switzerland. From 1998 to April 2004 he was co-founder and MD of YAbA Ltd and secured venture capital to develop and manufacture human and veterinary diagnostic products. He was a member of the Scottish Government's Life Sciences Advisory Board where he chaired its Technology Workstream from 2009-2011. Scott is a Director of Benenox Ltd and Marine Biotech Ltd.

Scott is a Chartered Engineer and holds an Honours Degree in Engineering from Edinburgh Napier University and a MBA from Edinburgh University. He is a Fellow of the Institute of Engineering and Technology and a Fellow of the Institute of Mechanical Engineers. He is a former Scientific Member and Vice-Chair of Medical Research Scotland and current advisory board member with Promedim Ltd. Scott also forms the Health Innovation Partnership Industry Liaison Team in partnership with the Scottish Government. He is a member of the Advisory Board of the Scottish LifeSciences Association.


 

Related Stories

Medical Research Scotland STV News Bulletin

Medical Research Scotland announces an innovative change in funding stream

BIOMEDICAL COMPANIES SET FOR CHARITY BOOST IN SCOTLAND